soft tissue sarcoma is determined by histological subtype, tumor size, localization, grade and the presence of metastases. [3] [4] [5] Despite great progress in surgery and multimodal therapy of nonmetastatic tumors, local control and limb salvage remain major challenges in large, high grade or recurrent tumors. [6, 7] Multimodal treatment of soft tissue sarcomas with chemotherapy and irradiation has been introduced in the seventies of the last century. [8] The mainstay of therapy of non-metastasized soft tissue sarcomas is complete surgical resection combined with irradiation in large, high grade tumors which are located deep to the superficial body fascia. [9, 10] Radiation may be administered pre-or postoperatively.
Neoadjuvant irradiation may facilitate tumor resection by devitalization and downsizing of the tumor. [11] Furthermore, vital structures such as organs, nerves or vessels may be preserved from radiation toxicity since the radiation field is smaller in the preoperative setting. [12, 13] Chemotherapy, definitive radiotherapy or chemotherapy combined with irradiation may be applied in locally advanced or irresectable tumors. [9, 10, [14] [15] [16] In case of locally advanced tumors, chemotherapy may be combined with heat. [17] Doxorubicin and ifosfamide are the most commonly administered chemotherapeutic agents. Yet, in the last decades a number of other promising substances have been tested in phase II and III trials with promising results. [18] Sunitinib is a small molecular inhibitor that acts on the transmembrane receptor tyrosine kinases PDGFR, VGFR, c-Kit, FLOT3 and CSF 1R that regulate vital cell functions such as proliferation, differentiation and cell death. Preclinical tumor models demonstrated anti-tumoral and anti-angiogenic activity of sunitinib. [19, 20] Soft tissue sarcomas are highly vascularized and show an overexpression of VEGFR and other receptor tyrosine kinases. [21] [22] [23] Therefore soft tissue sarcomas seem to be suitable for the treatment with anti-angiogenic substances. Accordingly, previous clinical studies demonstrated promising results of sunitinib and other receptor tyrosine kinase inhibitors in advanced soft tissue sarcoma. [24] [25] [26] The rationale behind a combination of irradiation and sunitinib is the possible additive or even synergistic effect of both treatment modalities. It is well known that tumor vascularization is chaotic and exhibits poor function due to an imbalance of pro-and anti-angiogenic factors. [27] The administration of anti-angiogenic agents such as sunitinib may "normalize" the chaotic neovascularization and thus decrease tumor hypoxia and increase the efficacy of radiation therapy. [28] Preclinical experiments demonstrated increased efficacy of irradiation if combined with anti-angiogenic substances. [20, 29] 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y Furthermore they contradict the hypothesis that treatment with anti-angiogenic substances may cause radiations resistance due to tumor hypoxia.
Kao et al. published the first feasibility study of sunitinib combined with percutaneous irradiation. [30] Primary end point of the study was dose limiting toxicity of sunitinib in oligo-metastasized patients of different primary tumors. The irradiated lesions were maximal 6 cm in size and were irradiated with 40-50 Gy. Sunitinib was given in an 4 weeks on and 2 weeks off regimen. Dose limiting toxicity occurred only in patients with 50mg sunitinib daily (grade 4 myelosuppression and grade 3 nausea and vomiting).
Complete or partial remission according to RECIST was achieved in 59% of the patients. Although the results of the study are promising, the included patients cannot be compared with soft tissue sarcoma patients in general. Soft tissue sarcoma are frequently large tumors at critical anatomic sites where irradiation inevitably involves vital organs or major vessels and nerves. The combination of radiotherapy and tyrosine kinase inhibitors may cause excessive toxicity in these cases. Therefore further evaluation of the toxicity of combined regimens is indicated. [31] Here we present the protocol of a phase I trial of concurrent sunitinib and irradiation in soft tissue sarcoma patients. 
Methods and analysis

Design
This is an open-label, single arm, national phase I trial performed at two study centers of sunitinib given concurrently to preoperative irradiation in patients with soft tissue sarcoma (figure 1).
Aims
1.
To describe the toxic effects of sunitinib given concurrently with preoperative radiotherapy to patients with soft tissue sarcoma.
2. To describe any preliminary evidence of anti-tumoral activity of the study treatment (imaging and pathological response).
3. To assess postoperative morbidity of tumor resection after preoperative treatment with sunitinib and irradiation.
Patient Population
The aim was to include all patients with soft tissue sarcomas that require preoperative irradiation and subsequent resection. Therefore not only patients with primary tumors but also patients with local recurrences will be eligible unless the primary tumor has been irradiated. Patients with metachronous singular metastases may be included if the singular metastatic lesion shall be treated by irradiation and surgery.
Inclusion and exclusion criteria are displayed in table 1. 
Treatment
Patients will receive Sunitinib and irradiation as neoadjuvant treatment before tumor resection ( figure   1 ). The administration of sunitinib concurrently to radiation therapy will be the study intervention.
Staging before study inclusion and re-staging before tumor resection will include magnetic resonance imaging of the tumor site and a thoracic computer tomography. These cross sectional images shall be performed within four weeks before study inclusion and shortly before tumor resection which is 
Radiation Therapy
Intensity modulated radiation therapy will be applied (IMRT) according to standard protocols of the University Medical Center Mannheim. [32] The dose of IMRT will be 50.4 Gy (median PTV dose) given in 28 fractions within 5 ½ weeks. All patients will be adequately immobilized depending on the body site during irradiation including ABC breathhold technique for locations with relevant breathing cycle dependent movement. A CT simulation will be performed before administration of irradiation. According to calculated 3D models derived from the planning CT the gross tumour volume (GTV) will be defined. In general, the clinical target volume (CTV) will be the GTV with a two cm margin axially. The margin placed around the GTV in the superior-inferior direction will be five cm. The planning target volume will be the CTV with a five mm margin. Lager PTV -CTV margins may apply in rare cases when no IGRT and/or breathhold is possible. The dose constraint for the small intestine will be 45Gy at the maximum and the mean dose for kidneys shall not be greater than 10 Gy. Optimized dose distributions will be obtained from an inverse planning algorithm (Monaco, Elekta, Stockholm). Treatment will be performed using step-and-shoot IMRT or volumetric modulated arc therapy (VMAT) with expected daily treatment times of less than 10 minutes. A strip of two to three cm will be spared in case of extremity STS.
Surgery
Surgery will be planned 5-8 weeks after completion of neoadjuvant treatment with sunitinib and irradiation. In extremity STS, en bloc resection with wide margins (1-2cm of uninvolved tissue or intake adjacent fascial layer) will be performed whenever possible. When the tumor is abutting neurovascular bundles, the adventitia or epineurium will be taken as the margin of resection. When encasement or infiltration of the neurovascular bundle is present, they will be resected and reconstructed if appropriate. In case of infiltration of the bone, the periosteum will be taken en bloc with the tumor.
Plastic reconstruction (e.g. free or pediculated flaps) will be used whenever necessary. In retroperitoneal sarcoma the surgical standard procedure for the majority of the patients comprises multivisceral resection as principle, with colectomy, nephrectomy, and resection of abdominal wall musculature or, respectively, the psoas muscle in order to achieve an R0 resection of the retroperitoneal compartment.
Resection of the aorta, inferior vena cava, iliac vessels, femoral nerve, diaphragm, duodenum or pancreas will only performed if macroscopic invasion is present. 
Dose escalation of sunitinib
According to a 3+3 phase one trial design sunitinib will be escalated in two dose levels. The starting dose of sunitinib will be 25 mg. The second dose level will be 37.5mg. The dose escalation scheme is described in table 2. The first three patients will be included into dose level one (25mg sunitinib). Before patients may be included into the second dose level treatment of all patients in the first dose level including combined sunitinib and irradiation and tumor resection must be completed. Intrapatient dose escalation is not permitted. 
First dose level (25mg)
• If 0/3 patients exhibit dose limiting toxicity (DLT) at the first dose level dose escalation at the second dose level (37.5mg) will begin in the second cohort.
• If 1/3 patients exhibit DLT at the first dose level the first dose level will be expanded to a total of 6 patients.
o If no further DLT events will be seen dose escalation to the second dose level can begin.
o If one or more further DLT events are seen the dose will not be escalated and no does will be recommended for phase II.
• If 2/3 patients suffer from DLT the dose will not be escalated.
Second dose level (37.5mg)
• If 0/3 patients exhibit dose limiting toxicity (DLT) at the second dose level, then the second does level will be recommended for phase.
• If 1/3 patient exhibits DLT events another 3 patients will be included in the second dose level. o If one or more further DLT events are seen the recommended dose for phase II will be the first dose level.
Anticipated toxicities
The most frequent risks from preoperative irradiation are skin and gastrointestinal toxicities. The most frequent adverse events experienced within studies of sunitinib were gastrointestinal toxicities, skin toxicities, hypertension peripheral edema, altered taste, headache, back pain, arthralgia, extremity pain, cough, dyspnea, anorexia, fatigue, fever, and bleeding. Thromboembolic events, leuco-and lymphopenia, left ventricular dysfunction, pancreatitis and liver failure were the most frequent severe adverse events (CTCAE grade 3-5). The additional administration of sunitinib may increase the radiation toxicity (e.g. increased gastrointestinal toxicity in retroperitoneal sarcoma or increased skin toxicity in extremity sarcoma) or may cause further adverse reaction that are yet unknown but related to the combination of both.
Dose limiting toxicities and dose adjustments
Any adverse event that occurs after intake of the first capsule of sunitinib until four weeks after last administration of sunitinib and that may be related to the drug will be documented and classified according to common toxicity criteria of adverse events (CTCAE 4.0). Dose limiting toxicities will be defined as follows:
• Any toxicity that causes a discontinuation of concurrent radiation therapy for more than 6 days
• Toxicity classified CTCAE 4.0 grade 4 or 5
• Toxicity classified CTCAE 4.0 grade 3 with the following exceptions:
o Arterial hypertension CTCAE 4.0grade 3 will only be regarded as dose limiting if it persists longer than 14 days despite adequate medical treatment.
o Hematologic toxicity CTCAE 4.0 grade 3.
o Elevated serum levels of of liver and pancreas enzymes of any CTCAE 4.0 grade will only be regarded as DLT if they are related with clinical symptoms of pancreatitis, hepatitis or liver failure. In case of dose limiting toxicities the administration of Sunitinib must be stopped. After recovery from toxicity to CTCAE grade 1 Sunitinib will be re-introduced in a reduced dose (25mg instead of 37.5mg or 12.5 instead of 25mg). In case of hematologic toxicity CTCAE grade 3 Sunitinib will be reduced (37.5 to 25mg or 25 to 12.5mg) until recovery to CTCAE grade 1. In case of prolonged toxicity of any CTCAE grade the dose of Sunitinib may also be reduced temporarily (37.5 to 25mg or 25 to 12.5mg). After recovery from toxicity to CTCAE grade 1 Sunitinib will be re-introduced in the original dose.
End points
Primary end points of the study are the determination of the dose limiting toxicity and the recommended phase II dose of sunitinib given concurrently to percutaneous irradiation as neoadjuvant treatment for soft tissue sarcoma.
-The recommended dose of Sunitinib will be dose level 2 (37.5mg) if not more than 0/3 or 1/6 patients in dose level 1 AND dose level 2 develop DLT.
-The recommended dose of Sunitinib will be dose level 1 (25mg) if not more than 0/3 or 1/6 patients develop DLT AND 2 or more patients develop DLT in dose level 2.
-No recommended dose will be defined if 2 or more patients develop DLT in dose level 1.
Secondary end points are pathologic and imaging response to the treatment and postoperative morbidity of tumor resection.
-Pathologic response will be defined as the fraction of non-viable tissue in the resection specimen -Imaging response will be defined according to RECIST and Choi criteria -Postoperative morbidity until the 30th postoperative day will be documented according to CTCAE grade 4.
Screening and assessment of end points
The study will be performed on an outpatient basis. Patients who present with primary or recurrent tumors or singular metachronous metastasis will be screened. Eligibility criteria will be assessed by review of biopsy histology and imaging, clinical examination and further organ function tests. This will include interrogation for pre-existent diseases and medication, clinical examination, differential blood count and determination of serum levels of kidney, hepatic and pancreatic enzymes, ECG and cardiac ultrasound. The investigator will explain the nature of the trial, its purpose, procedures as well as the potential risks and benefits. If inclusion criteria are met, informed consent will be obtained and the To assess the primary end point toxicity, study visits including clinical examination, interrogation for adverse events, laboratory tests and ECG will be performed on a weekly basis until the fourth week after completion of radiation therapy. As described above toxicity will be classified according to CTCAE 4.0.
To assess the secondary end point tumor response restaging with thoracic computertomography and magnetic resonance imaging of the tumor site will be performed before tumor resection which will be scheduled 5 to 8 weeks after completion of radiation therapy.
To assess the secondary end point postoperative morbidity there will be a study visit between the 30 th and 40 th day after the operation which includes review of the reports of the operation, the perioperative hospital stay and the histopathological examination.
Statistics
Sunitinib will be given in two dose levels according to a classical3x3 design. The total number of patients will thus lay between 2 at minimum and 12 at maximum. Only two patients will be treated if the first two patients in the first dose level both show a DLT. Twelve patients will be treated if a DLT occurs in one patient out of the first three in each dose level.
The power properties of the applied 3+3 design are as follows: Assuming an unacceptable high true DLT rate of 50% the probability to observe at least 1 DLT out of 3 patients is given by 87.5%, the probability to observe at least 2 out of 6 patients, which means no further dose escalation, is given by 89.1%. If the true DLT rate is 40 %, then the probabilities are given by 78.4% and 76.7%, respectively. Consequently, the power properties of the 3x3 design are appropriate in the context of a phase I trial.
Primary and secondary end points will be analyzed descriptively by the measures of the empirical distribution. For continuous data means and standard deviations, minimal and maximal values and median and quartiles will be calculated. For categorical data absolute and relative frequency will be given. All analyses will be performed using SAS version 9 or higher (SAS Institute Inc., USA).
Setting
Sponsor of the study is the University of Heidelberg, Germany. The trial is coordinated by the Division of Surgical Oncology of the Department of Surgery of the University Medical Center Mannheim, University The analysis of the primary and secondary end points will be performed immediately after completion of data collection which is expected for 2014. We aim to disseminate the results by publication in a peerreviewed journal and to present the study at national and international sarcoma and oncology meetings. 
Discussion
We present here the study protocol of an innovative and promising neoadjuvant therapy for soft tissue sarcoma combining radiation therapy and the anti-angiogenic multityrosine kinase inhibitor sunitinib.
Although single agent toxicity of sunitinib is well known we chose toxicity as primary end point since excessive toxicity of the combination may impair completion of standard radiation therapy and surgery. [31] For the same reason postoperative morbidity was chosen as a secondary end point.
The classical 3x3 dose escalation was selected because possibly effective dose levels known from previous single agent trials. Sunitinib is approved for a 4 weeks on/2 weeks off regimen at a dose of 50mg. Alternatively a continuously dosing of 37.5mg may be applied.
[33] The latter dosing is suitable for combination with preoperative radiation therapy and therefore was chosen as the final dose level.
If the combination of sunitinib and radiation therapy proves to be well tolerable in the neoadjuvant setting we plan to proceed to perform a multicenter phase II trial focusing on local tumor control.
Regarding the promising results of other multi tyrosine kinase inhibitors for metastatic disease we may then consider to combine neoadjuvant sunitinib and irradiation with adjuvant sunitinib. [24] [25] [26] 
Trial status
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